BIONET has always strongly believed in the motto “Quality, Professional, and Caring” as it aims to improve the quality of human life accompanied business operation with contribution to the community. The team of BIONET has devoted to transforming R&D accomplishments into marketable services in both of the major fields, application of stem cell and genetic testing. As the company established a firm foundation in scientific basis, it resulted in a solid record of revenue and profit. Consequentially, BIONET successfully completed initial public offering (IPO) and became the first public listed company in the stem cell and genetic industry of Taiwan.

Although BIONET was oriented in cord blood private banking originally, the company continued on developing advanced products in relative fields. In 2005, BIONET initiated the exclusive prenatal genetic testing for spinal muscular atrophy (SMA) screening, successfully applying research-based expertise to commercialization, thus far there has been over 100,000 mothers-to-be carrying out this test and thousands of SMA gene carriers has been identified. One may arguably state that knowing this information in advance, effective prevention could be taken and subsequently the medical expense of which to the society could be reduced.

In addition to prenatal SMA genetic testing, BIONET had introduced another two new services of umbilical cord mesenchymal stem cell (MSC) and adult peripheral blood stem cell (PBSC) storage during the period of 2003 to 2005. Not much later in 2006, a new service of stem cell revitalizer (SCR) storage was also launched, as the first step BIONET took onto the field of bio-cosmetology.

In 2008, the arsenal of BIONET was further expanded as four additional advanced services being initiated, including prenatal testing for Down syndrome, pre-implantation genetic diagnosis (PGD), dental pulp stem cell (DPSC) storage service, and preventive genetic testing. BIONET provides a great diversity of services and yet cease to increase, as the integrated team of BIONET kept developing new business models and carrying out research in multiple related but distinct fields.